As of June 18, 2026, Vera Therapeutics's top three insider holders are Capital Lp Commodore (TenPercentOwner, 4.40Mn shares), Patrick G Enright (Director, 3.60Mn shares), Venture Partners X, L.P. Sofinnova (TenPercentOwner, 3.47Mn shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Beth C Seidenberg | - | 0 | 1,737,383 | 14 Mar, 2023 |
| Patrick G Enright | - | 0 | 3,596,593 | 25 Jun, 2025 |
| Group Inc. Carlyle | - | 0 | 2,960,231 | 19 Aug, 2022 |
| Jane Wright-Mitchell | Chief Legal Officer | 42,403 | 0 | 25 Mar, 2026 |
| Venture Partners X, L.P. Sofinnova | - | 3,467,156 | 0 | 08 Feb, 2023 |
| Maha Katabi | - | 0 | 2,793,987 | 25 Mar, 2024 |
| David Lee Johnson | Chief Operating Officer | 45,727 | 0 | 25 Feb, 2026 |
| William D. Turner | Chief Regulatory Officer | 45,313 | 0 | 25 Feb, 2026 |
| Capital Partners Iv, Llc Longitude | - | 0 | 1,714,285 | 08 Feb, 2023 |
| Capital Lp Commodore | - | 0 | 4,400,000 | 12 Jan, 2024 |
| Joanne Curley | Chief Development Officer | 26,962 | 0 | 23 Aug, 2023 |
| Celia Lin | Chief Medical Officer | 11,010 | 0 | 23 Aug, 2023 |
| Marshall Fordyce | President And Ceo | 257,163 | 0 | 25 Feb, 2026 |
| Joseph R Young | Svp, Finance, Chief Acct Offcr | 75,754 | 0 | 16 Mar, 2026 |
| Sean Grant | Chief Financial Officer | 114,181 | 0 | 25 Feb, 2026 |
| Robert Brenner | Chief Medical Officer | 50,947 | 0 | 25 Feb, 2026 |
| Jason S Carter | Chief Legal Officer | 49,136 | 0 | 25 Nov, 2025 |
| Laurence Matthew Skelton | Chief Commercial Officer | 64,218 | 0 | 25 Feb, 2026 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 14 Apr, 2026 | Marshall Fordyce | Class A Common Stock | D | 14,130 | $43.66 | 244,065 | D | S |
| 14 Apr, 2026 | Marshall Fordyce | Class A Common Stock | D | 7,921 | $44.58 | 236,144 | D | S |
| 14 Apr, 2026 | Marshall Fordyce | Class A Common Stock | D | 900 | $45.51 | 235,244 | D | S |
| 23 Mar, 2026 | Jane Wright-Mitchell | Class A Common Stock | A | 42,403 | $0.00 | 42,403 | D | A |
| 23 Mar, 2026 | Jane Wright-Mitchell | Class A Common Stock | A | 42,403 | $0.00 | 42,403 | D | A |
| 23 Mar, 2026 | Jane Wright-Mitchell | Class A Common Stock | A | 42,403 | $0.00 | 42,403 | D | A |
| 23 Mar, 2026 | Jane Wright-Mitchell | Stock Option (right to buy) | A | 56,850 | $0.00 | 56,850 | D | A |
| 23 Mar, 2026 | Jane Wright-Mitchell | Stock Option (right to buy) | A | 56,850 | $0.00 | 56,850 | D | A |
| 23 Mar, 2026 | Jane Wright-Mitchell | Stock Option (right to buy) | A | 56,850 | $0.00 | 56,850 | D | A |
| 13 Mar, 2026 | Joseph R Young | Class A Common Stock | A | 10,000 | $3.94 | 75,754 | D | M |
| 13 Mar, 2026 | Joseph R Young | Class A Common Stock | A | 10,000 | $3.94 | 75,754 | D | M |
| 13 Mar, 2026 | Joseph R Young | Class A Common Stock | A | 10,000 | $3.94 | 75,754 | D | M |
| 13 Mar, 2026 | Joseph R Young | Stock Option (right to buy) | D | 10,000 | $0.00 | 38,589 | D | M |
| 13 Mar, 2026 | Joseph R Young | Stock Option (right to buy) | D | 10,000 | $0.00 | 38,589 | D | M |
| 13 Mar, 2026 | Joseph R Young | Stock Option (right to buy) | D | 10,000 | $0.00 | 38,589 | D | M |
| 05 Mar, 2026 | Christopher Hite | Stock Option (right to buy) | A | 24,937 | $0.00 | 24,937 | D | A |
| 23 Feb, 2026 | Joseph R Young | Class A Common Stock | D | 3,117 | $41.98 | 64,722 | D | S |
| 23 Feb, 2026 | Laurence Matthew Skelton | Class A Common Stock | D | 1,582 | $41.98 | 64,218 | D | S |
| 23 Feb, 2026 | Marshall Fordyce | Class A Common Stock | D | 16,925 | $41.98 | 257,163 | D | S |
| 23 Feb, 2026 | Joseph R Young | Class A Common Stock | D | 3,117 | $41.98 | 64,722 | D | S |